Search Results

Immunocore Holdings plc today announced that management will participate in the Jefferies Global Healthcare Conference.

Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”) today announces randomization of the first patient in the PRISM-MEL-301 trial, assessing the efficacy and safety of brenetafusp (IMC-F106C; PRAME-A02), in combination with nivolumab, in first-line advanced or metastatic cutaneous melanoma.

Immunocore Holdings plc presented three posters about KIMMTRAK® for the treatment of patients with unresectable or metastatic uveal melanoma at the 2024 ASCO Annual Meeting.

Immunocore Holdings plc presented two posters at the 2024 Conference on Retroviruses and Opportunistic Infections.

Immunocore Holdings plc, a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, announced that management will participate in the following investor conferences in April.

Immunocore Holdings plc will present Phase 1 expansion data for brenetafusp, the first off-the-shelf ImmTAC therapy targeting PRAME, in patients with late-line cutaneous melanoma, all previously treated with anti-PD1 and the vast majority having received ipilimumab, at the 2024 American Society of Oncology Annual Meeting commencing on 31 May.

Immunocore Holdings plc, a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, announced its financial results for the first quarter ended March 31, 2024 and provided a business update.

Immunocore reports updated Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024

Immunocore Holdings plc, a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, announced that management will participate in the following investor conferences in March.

Immunocore Holdings plc, a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, announced that the TEBE-AM Phase 2/3 clinical trial has been converted into a Phase 3 trial.